These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1267 related articles for article (PubMed ID: 9829753)

  • 1. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
    Klingemann HG; Wong E; Maki G
    Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel telomerase-based approach to detect natural cell-mediated cytotoxic activity against tumor cells in vitro.
    Faraoni I; Cottarelli A; Giuliani A; Bonmassar L; Rossi L; Bonmassar E
    J Immunol Methods; 2005 Oct; 305(2):162-72. PubMed ID: 16165149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor therapeutic potential of activated human umbilical cord blood cells against leukemia and breast cancer.
    Joshi SS; Tarantolo SR; Kuszynski CA; Kessinger A
    Clin Cancer Res; 2000 Nov; 6(11):4351-8. PubMed ID: 11106253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer (LAK) cell purging of bone marrow.
    Cramer DV; Long GS
    Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ultraviolet-B irradiation on human LAK and NK cytotoxic activity.
    Yaron I; Zakheim AR; Oluwole SF; Hardy MA
    Cell Immunol; 1995 Oct; 165(2):168-76. PubMed ID: 7553880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.